Last reviewed · How we verify
MK2206 every other day
At a glance
| Generic name | MK2206 every other day |
|---|---|
| Also known as | MK2206 |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) (PHASE1)
- Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002) (PHASE1)
- A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010) (PHASE1)
- Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer (PHASE2)
- A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007) (PHASE1)
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK2206 every other day CI brief — competitive landscape report
- MK2206 every other day updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI